Lv2
120 积分 2025-12-26 加入
HYPERTROPHIC CARDIOMYOPATHY IN ICELAND IS CHARACTERIZED BY LOW EVENT RATE CLINICAL COURSE AND MYBPC3 FOUNDER MUTATION
1个月前
已完结
Hypertrophic cardiomyopathy overview: Genetics, screening, and treatment
2个月前
已完结
Impact of genotype-phenotype associations on prognosis in dilated cardiomyopathy
3个月前
已完结
Genotype-aortic phenotype correlations in Marfan syndrome: a systematic review and meta-analysis of Fibrillin-1 variants
3个月前
已关闭
LONG-TERM RESPONSE OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS TO MAVACAMTEN BASED ON GENOTYPE STATUS: INSIGHTS FROM VALOR-HCM TRIAL
4个月前
已关闭
LONG-TERM RESPONSE OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS TO MAVACAMTEN BASED ON GENOTYPE STATUS: INSIGHTS FROM VALOR-HCM TRIAL
4个月前
已关闭
Real-World Assessment of Mavacamten's Impact on Left Ventricular Systolic and Diastolic Functions in Obstructive Hypertrophic Cardiomyopathy: A 1-Year Single-Center Observational Study
4个月前
已完结
Abstract 4132223: Mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy: design of the Phase 3 SCOUT-HCM trial
4个月前
已关闭
皖公网安备34019202002308
